久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

China's influence on global oncology community hailed

By Zhou Wenting in?Shanghai | chinadaily.com.cn | Updated: 2023-12-19 17:00
Share
Share - WeChat
Han Baohui, honorary director of the department of respiratory medicine at Shanghai Chest Hospital Affiliated with Shanghai Jiao Tong University School of Medicine. [Photo provided to chinadaily.com.cn]

China's voice in the international oncology community is growing, and its innovations in lung cancer diagnosis and treatment have also benefited the world, said a leading domestic expert of lung cancer during an event held by ClinChoice in Shanghai on Dec 16.

Since 20 years ago, when China caught up with the boom of targeted therapy in the field of lung cancer, the country has experienced rapid development and has now become a leader in the world's second echelon of research in this realm, said Han Baohui, honorary director of the department of respiratory medicine at Shanghai Chest Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, during the event which hosted discussions about the research and development of innovative medicines.

"In terms of all the drug targets, China has far exceeded the European Union and Japan in the number of studies and papers, and is only second to the United States," he said.

Han pointed out that China has also taken the lead in the development of immunotherapy, an innovative oncology treatment method.

"China has approved 10 immunotherapy products for cancer treatment, including four imported and six homegrown ones, welcoming advanced treatments at an accelerated pace," he explained. "Also, some immunotherapy products from China have been approved and marketed in the US and Europe, benefiting many other patients besides those in China. For example, immunotherapy products by Chinese biotech companies such as Beigene and Junshi Biosciences have already been marketed in Europe and the US respectively in recent months."

Han noted that China's strength in oncology research is significant because this means Asian populations are better represented in global multicenter research programs.

Han then said he hopes to see some changes in the design of clinical research of new medicines. He explained that under current research requirements, only patients who meet certain criteria are included in a clinical study. As such, researchers should expand the scope as well as establish a subgroup of participants.

"Once a drug is marketed, various complex situations will arise. For example, some patients have lung cancer as well as severe chronic obstructive pulmonary disease (COPD) or diabetes, and doctors still have to do everything possible to treat them," said Han.

"The data obtained from this subgroup will greatly help guide physicians in terms of medication use after the new drug is marketed."

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 亚洲一区日韩一区欧美一区a | 国产欧美成人不卡视频 | 在线观看国产精品一区 | 亚洲国产亚洲片在线观看播放 | 免费观看欧美性一级 | 精品久久一区二区三区 | 欧美日中文字幕 | 国产微拍精品福利视频 | 男女福利视频 | 99视频在线播放 | 日韩在线视频不卡一区二区三区 | 伊人成人在线视频 | 韩国欧洲一级毛片免费 | 国产一级真人毛爱做毛片 | 日韩欧美中文字幕在线观看 | 成人国产在线观看 | 久久精品国产精品亚洲艾 | 亚洲高清视频在线观看 | 免费看欧美xxx片 | 亚洲国产欧美在线人成精品一区二区 | 国产成人一级 | 国产精品揄拍一区二区 | 亚洲成人一区二区 | 一级毛片真人不卡免费播 | 国内自产拍自a免费毛片 | 自拍视频一区 | 亚洲国产成人久久一区二区三区 | 国内精品久久久久影院网站 | 99精品国产成人一区二区在线 | 在线观看亚洲视频 | 草草影院ccyy免费看片 | 午夜男人女人爽爽爽视频 | 五月桃花网婷婷亚洲综合 | 台湾黄三级高清在线观看播放 | 亚洲精品理论 | 欧美精品xxxⅹ欧美 欧美精品不卡 | 午夜成年| 女人张腿让男桶免费视频网站 | a免费网站| 五月桃花网婷婷亚洲综合 | heyzo国产亚洲高清 |